OTCQX:MRVFF - Post by User
Comment by
daydream1on Feb 12, 2010 10:02am
370 Views
Post# 16779676
RE: RE: Why such a focus
RE: RE: Why such a focus
You said: "Now here is a potential big bonus for us: If the dermal animal studies are positive we will have an advantage over Volteren gel. So if there is no risk of skin cancer and no dangers in Pennsaid when used with sun screen, we will have a larger customer base. Otherwise, cover up with capris and pants. Two year studies started a while ago. This might be a great catalyst for the sp."
On which planet are you living on? Pennsaid patent protection will be over by the time the dermal studies are done. And, while we are looking in the future... can NRI extend its dermal studies to Pennsaid Plus? Not with out more data.
As for the future share price, with the finanacial problems in Greece and the economic slown down in Canada do not be surprise to see Pennsaid sales to be down from the last quatre and therefore revenues will be down. It will be still a couple of quarters before NRI US market sales can give an indication of how well Pennsaid does.
IMO 0.15 is not unrealistic.
Goodluck
D.